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A B S T R A C T
We used a proteomics approach (iTRAQ) to identify differentially expressed lung proteins during early
stages of the tobacco carcinogen, NNK-induced lung tumorigenesis (hyperplasia/atypia, 4–10 weeks and
adenoma, 25 week) prior to the detection of adenocarcinoma in A/J mice. We identiﬁed 790 proteins at
week 4 and 710 proteins at weeks 10 and 25 with >95% conﬁdence and a Local False Discovery Rate
estimation less than 5%. We have demonstrated that NNK altered multiple protein (e.g., Carbonyl
Reductase, Annexin A5/6, Selenbp1, Hmgb1 and Hsp90b1) expressions in early lesions which can be used
as potential biomarkers for early detection of lung cancer.
ã 2015 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Despite the fact that cigarette smoking is the most important
causal factor for lung cancer [1,2] global tobacco use continues to
rise; it is estimated that approximately 1.4 billion people in the
world currently smoke tobacco. [3] The poor ﬁve year survival rate
(16%) is due, in part, to the histologic heterogeneity and late stageAbbreviations: NNK4, -(methylnitrosamino)-1-(3-pyridyl)-1-butanone; p-XSC,
1,4-phenylenebis(methylene)selenocyanate; iTRAQ, isobaric tags for relative and
absolute quantitation; SCLC, small cell lung cancer; NSCLC, non-small cell lung
cancer; MS, mass spectrometry; IARC, International Agency for Research on Cancer;
ABI, Applied Biologicals Inc; TEAB, triethylammoniumbicarbonate; TCEP, tris-(2-
carboxyethyl) phosphine; LC, liquid chromatography; SCX, strong cation exchange;
MALDI, matrix assisted laser desorption ionization; CHCA, a-cyano-hydroxycin-
namic acid; MS/MS, tandem mass spectrometry; FDR, false discovery rate; PSPEP,
Proteomics System Performance Evaluation Pipeline; MIAPE, Minimum Informa-
tion About a Proteomics Experiment; EF, error factor; GO, gene ontology; PANTHER,
Protein ANalysis THrough Evolutionary Relationships; IPA, Ingenuity Pathway
Analysis; ECL, enhanced chemiluminescence; Cbr, carbonyl reductase [NADPH];
Hmgb1, high mobility group protein B1; Selenbp1, selenium-binding protein 1;
Hsp90b1, heat shock protein beta 1; RAGE, receptor for advanced glycation
endproducts.
* Corresponding authors. Fax: +1 717 531 0002.
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4.0/).diagnosis of lung cancer where current treatments, including
surgery, radiation, and chemotherapy, are less effective. [4].
Therefore, alternative approaches including early detection and
mechanistically-based preventive strategies are gravely needed to
combat this disease.
Clinically, lung cancer is classiﬁed into two main histological
types: small cell lung cancer (SCLC), accounting for 13% of cases,
and non-small cell lung cancer (NSCLC), accounting for 87% of
cases [5]. Most of the spontaneous and chemically induced lung
tumors developed in mice resemble that of the human NSCLC
subtype, adenocarcinoma [6–9] the major histological form
diagnosed in humans today. The A/J mouse has been utilized
extensively to study the carcinogenic effects of numerous tobacco
smoke carcinogens, including the tobacco-speciﬁc N-nitrosamine
4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), and the
impact of chemopreventive agents [10–13].
NNK is a potent and speciﬁc lung carcinogen independent of the
route of administration in A/J mice [14]; NNK is classiﬁed as a
human lung carcinogen by the International Agency for Research
on Cancer (IARC) [15]. The NNK-induced lung tumorigenesis in the
A/J mouse model has led to the identiﬁcation of different
histopathological stages of lung tumor development, i.e., from
hyperplasia to adenoma and from adenoma to adenocarcinomale under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
24 A. Das et al. / EuPA Open Proteomics 9 (2015) 23–33[10,16,17]; these stages closely resemble the progression of
smoking-related human non-small cell lung cancer (NSCLC) [18].
In a previous proteomic study utilizing the NNK A/J mouse
model, we identiﬁed several proteins that are differentially
expressed in lung adenocarcinoma [19]. However, differential
expression of proteins at end stage adenocarcinoma formation
could be considered a consequence of cancer development and
may not provide biomarkers for early detection of the disease.
Therefore, in the present study we examined for the ﬁrst time
differential expression of lung proteins during NNK exposure at
earlier stages of disease development (hyperplasia/atypia and
adenoma) using the proteomic approach isobaric Tags for Relative
and Absolute Quantitation (iTRAQ) [20–22]. Furthermore, we
examined the impact of dietary 1,4-phenylenebis(methylene)
selenocyanate (p-XSC), an established chemopreventive agent
[19], in this animal model on protein proﬁling in the lung of mice
that had been treated with NNK. We have demonstrated that NNK
altered multiple protein (e.g., Carbonyl Reductase, Annexin A5/6,
Selenbp1, Hmgb1 and Hsp90b1) expressions in early lesions which
can be used as potential biomarkers for early detection of lung
cancer.
2. Materials and methods
2.1. Chemicals, diets, and reagents
NNK was purchased from Toronto Research Chemicals Inc.
(North York, Ontario, Canada), cottonseed oil from Acros Organics
(Morris Plains, NJ), and diet from Dyets Inc. (Bethlehem, PA). p-XSC
was prepared in house as reported previously [23]. All iTRAQ
reagents and buffers were obtained from Applied Biosystems Inc.
(ABI, Foster City, CA), Promega (Madison, WI), and Sigma–Aldrich.
Reagents and buffers for immunoblot assays were purchased from
Invitrogen (Carlsbad, CA) and Bio-Rad Laboratories (Hercules, CA).
Primary and secondary antibodies were purchased from Abcam
(Cambridge, MA), Santa Cruz Biotechnology (Santa Cruz, CA), and
Cell Signaling (Danvers, MA). Chemiluminescent immunodetec-
tion reagents and autoradiography ﬁlms were purchased from GE
Healthcare (Piscataway, NJ) and Imaging Resources, Inc. (Seattle,
WA), respectively.
2.2. Animals and treatments
Fig. 1 illustrates the design of the animal bioassay. Female A/J
mice (ﬁve-weeks old) were obtained from The Jackson LaboratoryFig. 1. Experimental design of NNK-induced lung tumorigenesis A/J mouse model. NNK 
prior to the start of NNK treatment and continued until termination at week 32. During sp
reached after NNK treatment, 6-10 mice/group were sacriﬁced and evaluated for histo(Bar Harbor, ME). Following quarantine for two weeks, mice were
distributed by weight into three groups (40 mice per group) as
follows: group 1, vehicle (cottonseed oil); group 2, NNK; group 3,
NNK + p-XSC (10 ppm as selenium in the diet), this dose was
selected based on demonstrated efﬁcacy and tolerance without
any adverse side effects [24]. Diet preparation and assessing the
stability of p-XSC in the diet under the conditions of the bioassay
were performed as described [23,25]. At 7 weeks of age, mice in
groups 2 and 3 received 3 mmol NNK in 0.1 ml cottonseed oil by
intragastric administration, once weekly for 8 weeks (total dose:
24 mmol per mouse) to induce lung tumors. To follow the
progression of lung tumor development, 5–10 mice per group
were sacriﬁced by CO2 asphyxiation at ﬁve speciﬁc time points
(4, 10, 19, 25 and 32 weeks) during which histopathological stages
of disease in the lungs were expected to be prominent, i.e.,
hyperplasia/atypia, adenoma, and adenocarcinoma [10,16,17].
Mice were perfused with approximately 20 ml of cold PBS to
remove blood constituents from the lungs during sacriﬁce. Visible
tumors (1–3 mm) on the outer surface of the lungs were tabulated
during necropsy by careful examination under a dissecting lamp.
Tumor incidence (% mice with tumors) and multiplicity (number of
tumors/mouse) were recorded. To maximize the use of the lungs,
the ﬁve lobes (one left lobe and four right lobes: apical, cardiac,
diaphragmatic, and azygous) were separated. For protein analysis
and histology, the left and right apical lobes were selected and each
lobe was cut in half and processed accordingly (top halves used for
protein analysis and bottom halves for histology). Lungs were ﬂash
frozen in liquid nitrogen and stored at 80 C for protein analysis or
ﬁxed in 10% neutral buffered formalin for 24 h for histology.
2.3. Histological examination of lung tissue
All H&E stained lung tissues were examined by an American
College of Veterinary Pathologist diplomate pathologist (T.C.)
blinded to treatment. Images of lung tissue were obtained with an
Olympus BX51 microscope and DP71 digital camera using Micro-
Suite Basic 2.6 imaging software (Olympus America, Inc.). Lung
tissue sections were scored using standardized criteria to conﬁrm
extent of pathological stage [6]. Fig. 2 depicts the histological
images of lesions. (a, b) airway and alveolar epithelial hyperplasia—
characterized as a diffuse or focal increase in number of respiratory
epithelial cells creating a crowded appearance, frequently luminal
protrusions were observed, sometimes forming papillae. A
regenerative phenotype consisting of small cuboidal cells with
cytoplasmic basophilia, open nuclei and increased nucleus:was administered weekly for 8 weeks. p-XSC was administered in the diet 2 weeks
eciﬁc time points of the bioassay at which stages of lung cancer were projected to be
pathology and/or protein expression.
Fig. 2. Photomicrographs of airway and alveolar epithelial hyperplasia, atypia, adenomas and adenocarcinomas in lungs of NNK-treated A/J mice.
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karyomegaly, nuclear hyperchromasia, increased N:C ratio, abnor-
mal nuclear shape, pseudoinclusions, cellular crowding, indistinct
cell borders, anisokaryosis, prominent hobnail appearance (arrow,
b), and non-basal mitotic ﬁgures. (c) alveolar epithelial hyper-
plasia—characterized by solitary or multiple foci of increased
epithelial cellularity distal to terminal bronchioles. The back-
ground of bronchioloalveolar architecture remained unaltered,
and epithelial cells were usually single layered. Round to oval
hypertrophic type II pneumocytes with abundant eosinophilic
cytoplasm lined the alveolar walls. Macrophages were present in
the alveolar lumina (arrow). (d, e) adenomas—characterized as
well circumscribed areas consisting of cuboidal to columnar cells
lining alveoli. The size was usually less than 5 mm in diameter and
retainedpreexisting alveolar structure. The adenoma in (d) had a
diameter of 1.5 mm. (e) Adenoma with progression in which a
distinct clone of cells (10 or more) appeared with hyperchromatic
nuclei and nuclear size greater than those found in cells of the
adenoma (arrow). (f) adenocarcinomas—characterized by cy-
tological atypia, increased frequency of mitoses, regional varia-
tion in growth pattern, papillary structures, sizes over 5 mm in
diameter, invasion of vessels, large airways or pleura, as well as
lymphatic and hematogenous metastases; adenocarcinoma with
airway invasion.
2.4. Lung protein preparation
Total lung protein from mice sacriﬁced at weeks 4, 10, and
25 was collected as described previously [19]. Protein concen-
trations were determined by the Lowry Protein Assay (Bio-Rad
Laboratories). Equal amounts of protein were pooled from ﬁve
mice in each group during the 4, 10, and 25 week sacriﬁce time
points and precipitated with cold acetone to remove potentially
interfering agents including salts, nucleic acids, lipids as follows.
Six volumes of 100% acetone (chilled, kept at 20 C) was added to
each group pool, vortexed, and placed at 20 C for approximately
2 h. To collect precipitated protein, group pools were centrifuged at
16,000  g for 10 min at 4 C. Protein pellets were then vortexed
twice with a 4:1 acetone-to-water solution and recovered by
centrifugation. The last wash was followed by drying in a
centrifugal vacuum concentrator. Final protein pellets were
resuspended in Milli-Q water, 0.1% SDS, and 1 M urea. Protein
recovery was determined by the Lowry Protein Assay (Bio-Rad
Laboratories).2.5. iTRAQ labeling
iTRAQ labeling was performed according to the recommenda-
tion of ABI with appropriate modiﬁcations as described [20,26].
The iTRAQ workﬂow is shown in Supplementary Information File 1.
For each group pool, 150 mg of protein was dried with a centrifugal
vacuum concentrator followed by resuspension in 0.5 M triethy-
lammoniumbicarbonate (TEAB, pH 8.5), 2% SDS, and reducing
reagent (5 mM tris-(2-carboxyethyl) phosphine, TCEP) for 1 h at
37

C. Group pools were then alkylated with 84 mM iodoacetamide
for 30 min at room temperature under dark and digested with
sequencing grade trypsin (Promega) at a trypsin to protein ratio of
1:15 overnight at 48

C. Efﬁcient digestion of group pools was
visualized by coomassie G-250 staining (Bio-Rad Laboratories) on a
10% SDS-PAGE gel (data not shown). Digested peptides from each
group pool were then labeled with respective isobaric tags
(mass = 113–115, 117–119) for 2 h before being combined.
2.6. 2D LC analysis
Labeled peptide mixtures were fractionated in the Penn State
Hershey Proteomics/Mass Spectrometry Shared Resource Core on a
passivated Waters 600 E HPLC system (Meadows Instrumentation,
Bristol, WI) and a Tempo LC MALDI Spotting System (ABI SCIEX) as
described previously [22]. Using a 4.6  250 mm PolySULFOETHYL
Aspartamide column (PolyLC, Columbia, MD) at a ﬂow rate of
1 ml/min, strong cation exchange (SCX) LC was performed for ﬁrst
dimensional separation on the Waters 600 E HPLC system. Two
buffers were prepared to separate samples: Buffer A contained
10 mM ammonium formate, pH 2.7, in 20% acetonitrile/80% water
and Buffer B contained 666 mM ammonium formate, pH 2.7, in 20%
acetonitrile/80% water. The HPLC separation gradient was as
follows: Buffer A at 100% (0–22 min following sample injection),
0% ! 40% Buffer B (16–48 min), 40% ! 100% Buffer B (48–49 min),
then isocratic 100% Buffer B (49–56 min), then at 56 min switched
back to 100% A to re-equilibrate for the next injection. The ﬁrst
26 ml of eluent (containing all ﬂow-through fractions) was
combined into one fraction and then 14 additional 2-ml fractions
were collected. All 15 of these SCX fractions were dried down
completely to reduce volume and to remove acetonitrile and
volatile ammonium formate salts, followed by resuspension in 9 ml
of 2% (v/v) acetonitrile, 0.1% (v/v) triﬂuoroacetic acid.
For 2D separation by reverse phase nanoﬂow-LC, each SCX
fraction above was autoinjected onto a Chromolith CapRod column
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the Tempo LC MALDI Spotting System. Additional buffers, C and D,
were prepared. Buffer C contained 2% acetonitrile, 0.1% triﬂuoro-
acetic acid, and Buffer D contained 98% acetonitrile, 0.1%
triﬂuoroacetic acid. The elution gradient was prepared as follows:
95% C/5% D (2 ml per minute ﬂow rate from 0 to 3 min, then 2.5 ml
per minute from 3 to 8.1 min), 5% D ! 38% D (8.1–40 min), 38%
D ! 80% D (41–44 min), 80% D ! 5% D (44–49 min) (initial
conditions). Flow rate was 2.5 ml/min during the gradient, and
an equal ﬂow of MALDI matrix solution (7 mg/ml recrystallized
CHCA (a-cyano-hydroxycinnamic acid), 2 mg/ml ammonium
phosphate, 0.1% triﬂuoroacetic acid, 80% acetonitrile) was added
post-column. The combined eluent was automatically spotted onto
a stainless steel MALDI target plate every 6 s (0.6 ml per spot), for a
total of 370 spots per original SCX fraction.
2.7. Tandem mass spectrometric analysis (MALDI TOF/TOF)
MS analyses of peptide fractions for subsequent identiﬁcation
and quantitation were performed on an ABI 4800 MALDI TOF/TOF
Analyzer (ABI SCIEX) as described previously [22]. MALDI target
plates (15 per experiment) containing peptides were analyzed in a
data-dependent manner on an ABI 4800 MALDI TOF/TOF Analyzer
(ABI SCIEX) along with 13 calibrant spots (ABI 4700 Mix). As each
plate entered into the instrument, a plate calibration/MS Default
calibration update was performed, followed by MS/MS default
calibration. MS Spectra were taken from 5500 MALDI Spots, using
500 laser shots per spot and laser intensity of 3000 or 3400. A
plate-wide interpretation was automatically performed in which
the highest peak of each observed m/z value was chosen for
subsequent MS/MS analysis (up to 7 precursor ions were selected).
MS/MS spectra were derived from 2500 laser shots at a laser power
of 3300 or 4000. Fragmentation of labeled peptides was induced
by the use of atmosphere as a collision gas with a pressure of
1.2–1.3  106 Torr. A total of 14,861 to 15,549 MS/MS spectra were
taken from experimental samples.
2.8. Peptide and protein identiﬁcation and quantitation
Protein identiﬁcations and relative iTRAQ quantiﬁcation were
performed from MS spectra using the Paragon Algorithm [27] and
further processed by Pro GroupTM algorithm as implemented in
Protein PilotTM v4.0 software (ABI-MDS Sciex). Protein PilotTM was
programmed to provide a thorough search of proteins taking into
account parameters for cysteine alkylation of proteins by
iodoacetamide and any potential biological modiﬁcations. MS
and MS/MS spectra were searched using the Mus musculus NCBI nr
database sequences containing 30,008 protein sequences (version
2011-03), plus concatenated reverse versions of itself, and
common human and laboratory contaminants (ABISciex_Conta-
minantDB_20070711); total of 60,328 protein sequences. Identi-
ﬁcations of proteins were only accepted with a Protein PilotTM
v4.0 Unused Score of >1.3, which corresponds to a peptide
conﬁdence level of >95%, and a “Local False Discovery Rate (FDR)”
estimation of no higher than 5%, as calculated by the PSPEP
(Proteomics System Performance Evaluation Pipeline) Algorithm
[28] from the rate of accumulation of “hits” from the Decoy
(reversed) database. This Local FDR estimate combined with the
Pro GroupTMAlgorithm included in Protein PilotTM v4.0 gives a very
conservative and fully Minimum Information About a Proteomics
Experiment (MIAPE)-compliant list of proteins identiﬁed [26].
iTRAQ reporter ion abundances in MS/MS scans were evaluated
using Protein PilotTM v4.0 software (ABI) for relative quantitation
of proteins as described previously [22]. For each peptide used for
protein identiﬁcation, areas of peaks at m/z 113-119, and 121 were
calculated. Peptides shared among different protein groups wereremoved before quantitation. Quantitative iTRAQ data were
exported into Microsoft Excel 2007 (Bellevue, WA) for further
analysis. Signiﬁcant differences in protein levels between groups
were only accepted based on a ﬁltering criteria which included
identiﬁcation and quantitation with 2 peptides, a p-value <0.05,
an EF<2 (i.e., standard deviation <20%), and a >1.2 or <0.8 fold-
change. Furthermore, highly abundant acute phase liver proteins
were excluded. Similar criteria have been utilized in previous
iTRAQ experiments with mouse models to indicate real biological
changes in tissues, including the lung [29].
2.9. Bioinformatics analysis (gene ontology and associated networks)
Identiﬁed proteins were assigned molecular functions and
biological processes based on uniﬁed Gene Ontology (GO)
consortium classiﬁcation [30] by the Protein ANalysis THrough
Evolutionary Relationships (PANTHER) classiﬁcation system
(http://www.pantherdb.org/, SRI International, Menlo Park, CA)
and were also imported into the Ingenuity1 Pathway Analysis (IPA)
Software v12710793 (Ingenuity Systems, Mountain View, CA) for
network and biological function analysis as described previously
[19].
2.10. Immunoblot analysis
Proteins from whole lung of mice treated with the vehicle
control, NNK, or (NNK + p-XSC) (15 or 25 mg/lane) were denatured
and resolved on a 12% SDS-PAGE gel and probed with the following
antibodies: anti-14-3-3 s (Abcam), anti-Cbr2 (Abcam), anti-
Hsp90b1 (Cell Signaling), and anti-b-actin (Santa Cruz). Bands
were detected using enhanced chemiluminescence reagents (ECL,
GE Healthcare) and developed with autoradiography ﬁlm (Imaging
Resources, Inc). For densitometric analysis, ﬁlms were scanned
using Bio-Rad's GS800Calibrated Densitometer. Quantitation of
protein levels was carried out using the Quantity One v4.5.0 1-D
Analysis Software (Bio-Rad Laboratories) and normalized to
b-actin levels.
2.11. Statistical evaluation
For tumor multiplicity, a Poisson regression was used to
statistically compare the number of tumors per mouse among the
three treatment groups. Signiﬁcant (p < 0.05) differences in lesion
multiplicity based on histological examination between groups
and immunoblot analyses was performed using Student's t-test.
3. Results and discussion
3.1. NNK-induced lung tumorigenesis and the impact of p-XSC
NNK exhibited (Fig. 3A) an increase in alveolar hyperplasia/
atypia up to week 19 (1.28  0.49 lesions per mouse) followed by a
prominent drop at week 25 (0.14  0.38 lesions per mouse). The
decrease in alveolar hyperplasia/atypia at week 25 coincided with
an increase in adenoma formation (0.57  0.53 lesions per mouse);
at this point, the transition from hyperplasia/atypia to adenoma
was evident. Furthermore, we did not detect adenocarcinoma at
the time points examined in this bioassay.
Dietary p-XSC (Fig. 3B) resulted in a signiﬁcant increase in
alveolar hyperplasia/atypia at week 10 (1.6  0.55 lesions per
mouse compared to 0.6  0.55 lesions per mouse, p = 0.02), but
returned to similar levels observed in mice receiving regular diet
(without p-XSC) and NNK thereafter. p-XSC had no effect on
adenoma formation at weeks 19 and 25 but signiﬁcantly reduced
the number of adenomas (Fig. 3C) only at week 32 (89% reduction,
p = 0.003).
Fig. 3. (A) Sequential appearance of alveolar hyperplasia/atypia, adenoma, and
adenocarcinomas identiﬁed in the lungs of mice treated with NNK alone at weeks 4,
10, 19, 25 and 32. (B) Number of alveolar hyperplasia/atypia lesions identiﬁed in the
lungs of mice at weeks 4, 10, 19, 25 and 32 with three treatment arms; vehicle, NNK
alone and NNK + p-XSC. (C) Number of adenoma lesions identiﬁed in the lungs of
mice at weeks 4, 10, 19, 25 and 32 with three treatment arms; vehicle, NNK alone
and NNK + p-XSC.
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and 10 weeks and a sharp drop at 25 weeks which coincided with
an increase in adenoma formation. Adenomas are proposed
precursors of adenocarcinoma development [6]; in general the
transition of adenoma to adenocarcinoma is detected beyond
30 weeks after NNK administration in the same model [16,31].
Consistent with previous studies [24,32] p-XSC signiﬁcantly
reduced lung adenoma multiplicity only at 32 weeks (Fig. 3C).
3.2. Protein proﬁle changes during the progression of NNK-induced
lung tumorigenesis
Proteins identiﬁed [19] in lung adenocarcinoma in the same
animal model in our previous study such as 14-3-3 isoforms and
annexin A5 are known to be associated with important biological
functions that are critical in lung carcinogenesis. However,
differential expression of proteins at end stage adenocarcinomaformation could be considered a consequence of cancer develop-
ment and may not provide biomarkers for early detection of
the disease. Therefore in the present study we focused on
identiﬁcation of proteins in early lesions.
Lung tissues at week 4 (alveolar hyperplasia/atypia), 10
(exhibited an increase of alveolar hyperplasia and atypia) and at
week 25 (exhibited an increase in adenomas) were selected for
iTRAQ proteomic analysis. iTRAQ experiments performed on
pooled lung tissue protein collected from mice (n = 5 mice/
treatment group) at week 4 led to the identiﬁcation of 790 proteins
and at weeks 10 and 25, 710 proteins with >95% conﬁdence and a
Local FDR estimation of no higher than 5%.
A pairwise comparison between groups at each of the selected
time points was performed by using the areas under the peaks at
m/z 113–115 and 117–119 Da. These masses are those of the
reporter ions derived from the iTRAQ reagents that were attached
to peptides and represent the expression level of proteins. A
representative MS and peptide MS/MS spectrum of the corre-
sponding amino acid sequence—AMAMELGPHK- used in the
identiﬁcation and quantitation of one of the proteins, the carbonyl
reductase 2 protein [NADPH] (Cbr) is shown in Supplementary
Information File 2. The relative intensities of the iTRAQ reporter
ions were used to quantify the relative Cbr protein expressions for
each experimental group at weeks 10 and 25.
At week 4, we found signiﬁcant changes in the relative
expression of 9 proteins between NNK (Group 2) and vehicle
controls (Group 1). Of these proteins, 7 (77.8%) were up-regulated
and 2 (22.2%) were down-regulated (Table 1). At week 10, we found
signiﬁcant changes in the relative expression of 29 proteins
between NNK (Group 2) and vehicle controls (Group 1), 5 (17.2%)
were up-regulated and 24 (82.8%) were down-regulated (Table 1).
At week 25, we found signiﬁcant changes in the relative expression
of 9 proteins between group 2 and Group 1, 3 (33.3%) were up-
regulated and 6 (66.7%) were down-regulated (Table 1).
In general, a unique set of proteins were modulated at each
disease stage, however, our results showed an overlap of certain
proteins between the different stages of NNK-induced lung
tumorigenesis including AHNAK nucleoprotein isoform 1 and
Cbr-2 between week 4 and 10; between weeks 10 and 25 an overlap
of kininogen-1 isoform 1 (Kng 1), high mobility group protein B1
(Hmgb1), selenium-binding protein 1 (Selenbp1), and endoplas-
min (also known as glucose-regulated protein 94 or heat shock
protein 90 beta, member 1, Hsp90b1) was observed.
3.3. Molecular functions and the biological impact of identiﬁed
proteins
In order to understand the biological functions of proteins that
were modulated during NNK-induced hyperplasia/atypia and
adenoma in mouse lung, the proteins were imported into the
Ingenuity Pathway Analysis (IPA) program. IPA identiﬁes molecular
relationships between proteins based on gene ontology and
functionality and can associate them to “seed” molecules to form
consolidated informational biological Networks. The proteins
modulated during NNK-induced lung tumorigenesis (4–25 weeks)
were characterized into three Networks with a score from 16 to 36;
top diseases and functions include Cancer, Cellular Development,
and Inﬂammatory Response. Figs. 4A and B show the top two
spider networks of the proteins along with the direct and indirect
relationships exhibited by the proteins during early development
of the tumorigenesis process (hyperplasia/atypia at week 4 and 10)
when Cbr2, Annexin A6, Hmgb1, and Selenb1 were all found to be
reduced signiﬁcantly. Detailed IPA analysis is presented in the
Supplementary File 3. Network in Fig. 4A has a score of 36 and
number of focus molecule is 15. Notable diseases and molecular
functions are inﬂammatory response, tissue development and
Table 1
Differentially expressed proteins in A/J mouse lung tissue during NNK treatment (week 4), alveolar hyperplasia and atypia development (week 10), and adenoma
development (week 25).





gi|12230036 Cytoplasmic dynein 1 heavy chain 1 Dync1h1 7.6560 0.0384 " Microtubule motor activity; hydrolase activity;
structural constituent of cytoskeleton
gi|12230036 Clathrin heavy chain 1 Cltc 5.4450 0.0162 " Structural molecule activity; protein binding
gi|13959396 Ras GTPase-activating-like protein
IQGAP1
Iqgap1 4.2073 0.0358 " Protein binding; small GTPase regulator activity
gi|47605547 Cysteine-rich protein 2 Crip2 2.0512 0.0087 " Structural constituent of cytoskeleton; DNA
binding; transcription factor activity
gi|38372382 GTPase IMAP family member 4 Gimap4 1.5849 0.0479 " Nucleotide binding; GTP binding
gi|38372382 Lamin-B1 Lmnb1 1.3183 0.0282 " Structural constituent of cytoskeleton
gi|61743961 AHNAK nucleoprotein isoform 1 Ahnak 1.2134 0.0405 " Protein binding
gi|6671688 Carbonyl reductase [NADPH] 2 Cbr2 0.6918 0.0057 # Oxidoreductase activity
gi|132956 60S Ribosomal protein L3 Rpl3 0.7727 0.0080 # Structural constituent of ribosome; nucleic acid
binding
Wk 4 (114:113)
gi|31982755 Vimentin Vim 2.2909 0.0108 " Structural constituent of cytoskeleton
gi|156231021 Kininogen-1 isoform 1 Kng1 2.2080 0.0189 " Protein binding; peptidase inhibitor activity
gi|31980648 ATP synthase subunit b,
mitochondrial
Atp5b 1.7378 0.0372 " Hydrolase activity, acting on ester bonds;
receptor activity; cation transmembrane
transporter activity; ligand-gated ion channel
activity
gi|6755863 Endoplasmin Hsp90b1 1.6596 0.0227 " Chaperone
gi|31542438 Cytochrome b5 type B Cyb5b 1.2823 0.0024 " Oxidoreductase activity
gi|19526792 Hematopoietic progenitor cell
antigen CD34 isoform 2
Cd34 0.7943 0.0033 # Carbohydrate binding; sulfate binding
gi|31981690 Heat shock cognate 71 kDa protein Hsp8 0.7379 0.0086 # Chaperone; repressor
gi|20072492 SEC14-like protein 3 Sec14l3 0.7311 0.0380 # Transmembrane transporter activity
gi|585658 Platelet endothelial cell adhesion
molecule isoform 2
Pecam1 0.6982 0.0032 # Receptor activity
gi|6753890 Dimethylaniline monooxygenase
[N-oxide-forming] 1
Fmo1 0.6668 0.0335 # Oxidoreductase activity
gi|227116353 Platelet glycoprotein 4 Cd36 0.6668 0.0339 # Receptor activity
gi|6754208 High mobility group protein B1 Hmgb1 0.6607 0.0064 # DNA binding;chromatin binding; receptor
binding; transcription factor activity
gi|8393866 Ornithine aminotransferase,
mitochondrial
Oat 0.6486 0.0133 # Transaminase activity
gi|31982186 Malate dehydrogenase,
mitochondrial
Mdh2 0.6427 0.0049 # Oxidoreductase activity
gi|53581 Annexin A6 AnxA6 0.6310 0.0034 # Calcium ion binding; protein binding; calcium-
dependent phospholipid binding
NP_033773 AHNAK nucleoprotein isoform 1 Ahnak 0.6310 5.69E-08 # Protein binding
gi|31543113 Plastin-2 Lcp1 0.6252 0.0410 # Sonstituent of cytoskeleton; cytoskeletal protein
binding
gi|6753244 Calmodulin Calm1 0.6081 0.0360 # Calcium ion binding; protein domain speciﬁc
binding; thioesterase binding; phospholipase
binding; phosphatidylinositol 3-kinase binding
gi|255003777 Glyoxalase domain-containing
protein 4
Glod4 0.6026 0.0350 # Lyase activity
gi|112293264 Protein disulﬁde-isomerase A3 Pdia3 0.5861 0.0005 # Protein disulﬁde isomerase activity
gi|84875537 Nucleolin Ncl 0.5598 0.0164 # RNA splicing factor activity, transesteriﬁcation
mechanism; DNA binding; RNA binding
gi|6680836 Calreticulin Calr 0.5546 0.0022 # Calcium ion binding
gi|117553604 Carboxylesterase 3 Ces1 0.5012 0.0283 # Hydrolase activity, acting on ester bonds;
receptor binding
gi|42415475 Protein disulﬁde-isomerase P4hb 0.5012 0.0002 # Protein disulﬁde isomerase activity
gi|22164798 Selenium-binding protein 1 Selenbp1 0.4966 0.0002 # Protein binding; selenium binding
gi|46559389 Angiotensin-converting enzyme
isoform 1
Ace 0.4875 0.0007 # Peptidase activity
gi|6671688 Carbonyl reductase [NADPH] 2 Cbr2 0.4246 8.91E-06 # Oxidoreductase activity
gi|8393739 Lysozyme C-2 Lyz2 0.4055 0.0349 # Hydrolase activity
gi|6671549 Peroxiredoxin-6 Prdx6 0.2582 0.0010 # Oxidoreductase activity; peroxidase activity
Wk 25 (118:117)
gi|6754208 High mobility group protein B1 Hmgb1 1.9953 0.0028 " DNA binding;chromatin binding; receptor
binding; transcription factor activity
gi|6755863 Endoplasmin Hsp90b1 1.4060 0.0048 " Chaperone
gi|45504394 Integrin b-1 Itgb1 1.3183 0.0217 " Receptor activity
gi|145301561 Carbonic anhydrase 1 Ca1 0.7516 0.0257 # Hydro-lyase activity
gi|6753060 Annexin A5 Anxa5 0.7311 0.0087 # Calcium ion binding; calcium-dependent
phospholipid binding
gi|7110705 Prothymosin a Ptma 0.7112 0.0059 # Histone binding
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gi|52695504 Talin-1 Tln1 0.5346 0.0006 # Structural constituent of cytoskeleton
gi|22164798 Selenium-binding protein 1 Selenbp1 0.5152 0.0016 # Protein binding; selenium binding
gi|156231021 Kininogen-1 isoform 1 Kng1 0.4786 0.0026 # Protein binding; peptidase inhibitor activity
a National Center for Biotechnology Information (NCBI).
A. Das et al. / EuPA Open Proteomics 9 (2015) 23–33 29hematological system. The distinct network “seeds” that were
identiﬁed in the network are Pkc, Jnk, ERK1/2, and IL1/2 and
notable proteins inclusion are Hmgb1 and ANXA6. Network in
Figure 4B has a score of 24 and number of focus molecule is 10.
Notable diseases and molecular functions are cancer, development
and function, and reproductive system. The distinct network
“seeds” that was identiﬁed in the network is TNF and notable
proteins inclusion are Cbr2 and Selenbp1. The distinct inferred
network “seeds” Pkc, Jnk, ERK1/2, TNF, and IL1/2 that were
identiﬁed in the Networks are known regulators of cellular growth
and survival.
3.4. The effect of NNK + p-XSC on protein expression
As described above, p-XSC did not inhibit the formation of
hyperplasia/atypia and adenoma (4–25 weeks); the reduction in
adenoma reached signiﬁcance only at 32 weeks which is consistentFig. 4. Ingenuity Pathway Analysis (IPA) Networks of Proteins Modulated during the P
identiﬁed two top Networks which included many of the proteins we identiﬁed in the iT
Pkc, Jnk, ERK1/2, and IL1/2 and notable proteins inclusion are Hmgb1 and ANXA6. (B) T
protein inclusion is Cbr2 and Selenbp1. Red indicates up regulation, green indicates 
inhibition, yellow indicates inconsistent ﬁnding with state of downstream molecule anwith our previous studies [24,32]. These results could explain the
lack of effect of p-XSC on the expression of the majority of proteins
that had been altered by NNK; only 7 proteins (bold in Table 2)
were further modulated by p-XSC in the lung of mice treated with
NNK. (Tables 1 and 2). These proteins included Cbr2, Selenium-
binding protein 1 and Annexin A6. However, several additional
proteins (total 22 proteins), that were not affected in mice treated
with NNK alone (Table 1), were signiﬁcantly modulated in the
presence of p-XSC at each sacriﬁce time point (Table 2). These
proteins are involved in top molecular and cellular functions, as
indicated by IPA, which include cell cycle regulation (protein
phosphatase 2a, catalytic subunit, a isoform, 14-3-3 h), glutathi-
one metabolism (glutathione S-transferase P1, glutathione
S-transferase Mu1, glutathione peroxidase 1), and lipid metabo-
lism (alcohol dehydrogenase 1, cytochrome P450 2B10 isoform 2,
cytochrome b5 type B, myristoylated alanine-rich C-kinase
substrate)rogression of Lung Tumorigenesis, imported from Table 1 at week 4 and 10. IPA
RAQ study. (A) The distinct network “seeds” that were identiﬁed in the network are
he distinct network “seeds” that was identiﬁed in the network is TNF and notable
down regulation, orange indicates predicted activation, blue indicates predicted
d ﬁnally grey indicates where effect is not predicted.
Table 2
Changes in the relative abundance of proteins in lung tissue during dietary administration of the chemopreventive agent p-XSC in NNK-treated A/J mice.






Wk 4 Proteins modulated by p-XSC (115:114)
gi|9506983 Protein phosphatase 2a, catalytic
subunit, a isoform
Ppp2ca 1.7865 0.0144 " Hydrolase activity; acting on ester bonds;
phosphatase activity; calcium ion binding
gi|52695504 Talin-1 Tln1 1.4454 0.0383 " Structural constituent of cytoskeleton
gi|70778915 Moesin Msn 1.3183 0.0498 " Structural constituent of cytoskeleton
gi|55976655 14-3-3 protein h Ywhah 1.2589 0.0294 " Protein binding
gi|56757667 Heat shock 70 kDa protein 1A Hspa1a/
Hspa1b
0.7112 0.0461 # Chaperone
gi|53581 Annexin A6 Anxa6 0.6546 0.0150 # Calcium ion binding; calcium-dependent
phospholipid binding
gi|22164798 Selenium-binding protein 1 Selenbp1 0.6310 0.0173 # Selenium binding; protein transport
gi|113336 AP-2 complex subunit a-2 Ap2a2 0.5916 0.0049 # Lipid binding; protein transporter activity
gi|13435450 Annexin A1 Anxa1 0.4018 0.0336 # Calcium ion binding; calcium-dependent
phospholipid binding
gi|113391 Alcohol dehydrogenase 1 Adh1 0.3767 0.0132 # Oxidoreductase activity
gi|22261823 SAM domain and HD domain-
containing protein 1
Samhd1 0.3532 0.0120 # Hydrolase activity
gi|20178023 Periaxin Prx 0.1556 0.0041 # Protein binding
gi|201969 Cytochrome P450 2B10 isoform 2 Cyp2b10 0.0608 0.0001 # Oxidoreductase activity
Wk 10 proteins modulated by p-XSC (115:114)
gi|10092608 Glutathione S-transferase P 1 Gstp1 4.6132 0.0004 " Transferase activity
gi|6754084 Glutathione S-transferase Mu 1 Gstm1 2.9923 0.0018 " Transferase activity
gi|130485277 Ferritin light chain 2 Ftl 2.1677 0.0127 " Oxidoreductase activity
gi|68131547 Histone H2B type 1-C/E/G Hist1h2bj/
Hist1h2bk
2.0137 0.0085 " DNA binding
gi|40254595 Dihydropyrimidinase-related
protein 2
Dpysl2 1.5417 0.0264 " Hydrolase activity
gi|84871986 Glutathione peroxidase 1 Gpx1 0.6607 0.0395 # Oxidoreductase activity; peroxidase activity
gi|31543942 Vinculin Vcl 0.3532 0.0031 # Structural constituent of cytoskeleton
gi|170172589 Periaxin isoform L Prx 0.3281 0.0281 # Protein binding
gi|126032329 Elongation factor 1-a 1 Eef1a1 0.2355 0.0422 # Translation factor activity; nucleic acid binding;
translation elongation factor activity
Wk 25 proteins modulated by p-XSC (119:118)
gi|10092608 Glutathione S-transferase P 1 Gstp1 6.1944 0.0004 " Transferase activity
gi|6754084 Glutathione S-transferase Mu 1 Gstm1 1.9770 0.0264 " Transferase activity
gi|6671549 Peroxiredoxin-6 Prdx6 1.5276 0.0255 " Oxidoreductase activity; peroxidase activity
gi|28173550 Septin-7 Sept7 0.8091 0.0296 # GTPase activity; structural constituent of
cytoskeleton; protein binding
gi|31542438 Cytochrome b5 type B Cyb5b 0.6026 0.0048 # Oxidoreductase activity
gi|6678768 Myristoylated alanine-rich C-
kinase substrate
Marcks 0.5754 0.0471 # Structural constituent of cytoskeleton; receptor
binding;cytoskeletol protein binding
gi|295054266 Spectrin a chain, brain isoform 2 Sptan1 0.5200 0.0253 # Acting capping
gi|112293264 Protein disulﬁde-isomerase A3 Pdia3 0.4018 0.0115 # Protein disulﬁde isomerase activity
gi|201969 Cytochrome P450 2B10 isoform 2 Cyp2b10 0.3873 0.0087 # Oxidoreductase activity
gi|6677837 Protein S100-A9 S100a9 0.2655 0.0203 # Calcium ion binding; receptor binding;
calmodulin binding
gi|70778915 Moesin Msn 0.2208 0.0053 # Structural constituent of cytoskeleton
gi|6671688 Carbonyl reductase [NADPH] 2 Cbr2 0.1318 0.0002 # Oxidoreductase activity
a National Center for Biotechnology Information (NCBI).
30 A. Das et al. / EuPA Open Proteomics 9 (2015) 23–333.5. Proteins identiﬁed in early lesions as potential biomarkers for
early detection of lung carcinogenesis
In the present study proteins identiﬁed (Table 1) as differen-
tially expressed at earlier stages of NNK-induced lung tumorigen-
esis (hyperplasia/atypia and adenoma) development were
associated with a vast array of important biological functions
including translation, cell-to-cell junction, xenobiotic metabolism,
transcription regulation, immune response, inﬂammation, cell
redox homeostasis, and cellular senescence. These biological
functions are often implicated in the pathogenesis of cancer
development.
Based on the availability of the antibodies and biological
function in tumor development certain proteins identiﬁed by
iTRAQ, were validated by immunoblot analysis. However, due to
multiple analyses (histopathology, iTRAQ, Western blots) from thesame limited source of lung tissue, it was not possible to validate
every discussed protein detected in iTRAQ by immunoblot analysis.
We selected Cbr and Hsp90b1 (also known as endoplasmin) for
immunoblot analysis [33,34]. Using the two approaches, we
showed down-regulation of Cbr expression pattern with NNK
treatment compared to vehicle at weeks 4 and 10 and no change at
week 25 (Fig. 5A). Cbr is in the class of oxidoreductase proteins that
are abundant in several tissues including the liver and lung [35].
They utilize NADPH to reduce aldehyde and ketone groups of many
endogenous and exogenous xenobiotic carbonyl compounds such
as the carcinogen (NNK) employed in this study and can provide
protection against reactive oxygen species (ROS) [35,36]. At mRNA
and protein levels, Cbr was found to be down-regulated in mouse
lung adenocarcinomas induced by NNK compared to adjacent
normal tissue [37,38]. Furthermore, low levels of Cbr in mouse lung
adenocarcinoma cell lines have higher metastatic potential than
A. Das et al. / EuPA Open Proteomics 9 (2015) 23–33 31cells with higher levels of Cbr [39] and low levels of Cbr have been
correlated with a poor prognosis in human NSCLC [40]. The results
of our iTRAQ experiment, and immunoblot analysis combined with
those reported in the literature [37–40] suggest that loss of Cbr
expression, which provides protection to the lung from tissue
damage, occurs early in the carcinogenic process, and may be
considered as a potential biomarker for early detection in lung
carcinogenesis. However in our study no change was observed in
the expression of Cbr protein in the presence of p-XSC (+NNK)
compared to NNK alone; it is likely that p-XSC exerts its effects on
Cbr expression beyond 25 weeks; this is consistent with the results
(Fig. 3C) demonstrating a signiﬁcant inhibition of lung adenoma
was observed only at week 32.
iTRAQ showed that HSP90b1 was upregulated at weeks 4,
10 and 25 but reached statistical signiﬁcant up-regulation only at
Weeks 10 and 25. Consistent with iTRAQ, immunoblot analysis
conﬁrmed that Hsp90b1 expression was up-regulated at week
10 but no signiﬁcant changes were observed at weeks 4 and 25
(Figure 5A).
Heat shock protein Hsp90b1, based on iTRAQ analysis, was up-
regulated during both alveolar hyperplasia/atypia and adenoma
development in our mouse model. Interestingly, the expression of
Hsp90b1 has been shown to be up-regulated in human lung cancer
tissue and other cancers [41,42] and was associated with poor post-
surgical survival time and lymphatic metastasis of lung cancer [41].
Hsp90b1 is involved in cellular adaptation and are involved in
cellular functions including maintenance of cytoarchitecture,
differentiation, and cytoprotection [43]. Our results combined
with those reported in the literature suggest that this protein may
be employed as a potential biomarker for early detection of lung
cancer development.
In our previous study [19], we found that the levels of 14-3-3 s
protein isoform were decreased in lung adenocarcinomas inducedFig. 5. Densitometric Analysis of Proteins Modulated During NNK-induced Lung Tumorig
conﬁrmed by immunoblot analysis at the NNK-induced alveolar hyperplasia/atypia and ad
the 14-3-3 s protein by immunoblot analysis and fold changes during adenoma in weby NNK and were subsequently recovered by p-XSC. In the present
study, although we did not detect 14-3-3 s by iTRAQ analysis,
western blot analysis showed a non-signiﬁcant increase in 14-3-
3 s expression in the lungs of mice treated with NNK compared to
vehicle-treated mice (Fig. 5B) at week 25. Similar results were
obtained at 10 weeks (data not shown). Whereas with p-XSC, 14-3-
3 s was signiﬁcantly up-regulated at week 25 (Fig. 5B) as well as at
week 10 (data not shown) compared to NNK alone and vehicle
treated mice. The up-regulation of the 14-3-3 s may be important
to the chemopreventive activity elicited by p-XSC, and more so
during progression from adenoma to adenocarcinoma. As de-
scribed in our previous study [19], 14-3-3 s was downregulated in
adenocarcinoma-induced by NNK but restored by p-XSC.
Selenbp1, known for its ability to bind to selenium, is a 56 kDa
protein whose function is not entirely understood aside from
participation in late stages of intra-Golgi protein transport [44].
Nevertheless, low levels of expression of Selenbp1 have been
associated with poor outcome in lung adenocarcinomas [45] and
decreased expression of Selenbp1 has been suggested to promote
tumor invasiveness in hepatocellular carcinoma [46]. In the
current study, we found Selenbp1 consistently down-regulated
in the lungs of mice treated with NNK during alveolar hyperplasia/
atypia and adenoma development and maybe considered as a
potential candidate for early detection; however, in line with its
lack of effect on these early lesions, p-XSC could not restore the
expression of this protein.
Hmgb1 is a highly conserved nuclear protein that binds to DNA
to promote access to transcriptional protein assemblies on speciﬁc
DNA targets to regulate gene expression [47]. Hmgb1 can also be
secreted from cells and through interaction with the receptor for
advanced glycation endproducts (Rage) activate the NF-kB
pathway to promote inﬂammation [48]. The Hmgb1-Rage interac-
tion has also been associated with cancer cell proliferation,enesis. (A) Cbr2 and Hsp90b1 were identiﬁed in iTRAQ as being modulated and were
enoma stages. *Signiﬁcant difference vs. vehicle control (p < 0.05) (B) Modulation of
ek 25; bars denoted by different letters indicate signiﬁcant difference (p < 0.05).
32 A. Das et al. / EuPA Open Proteomics 9 (2015) 23–33invasion, and migration [49,50]. Low levels of Hmgb1 in advanced
stages of NSCLC have been associated with poor therapeutic
outcome during chemotherapy and radiotherapy [51]. We found
Hmgb1 to be down-regulated in the lung during alveolar
hyperplasia/atypia development in NNK-treated mice and may
be employed as a potential biomarker for early detection of this
disease. As expected based on the non-signiﬁcant chemopreven-
tive effect of p-XSC on tumor yield, no change in the expression of
this protein was observed in the presence of p-XSC (+NNK)
compared to NNK alone.
We previously showed that the pro-apoptotic marker Annexin
A5, was down-regulated in NNK-induced lung adenocarcinomas
and was recovered by p-XSC [19]. In the present study both
Annexin A5 and A6 were signiﬁcantly down-regulated in the lungs
of NNK-induced alveolar hyperplasia/atypia and adenoma devel-
opment and both can be used as potential biomarkers for early
detection; as expected p-XSC appeared to have no effect at either
time point.
4. Conclusions
We have demonstrated that multiple protein (e.g., Cbr, Annexin
A5/6, Selenbp1, Hmgb1 and Hsp90b1) expressions are altered in
early lesions (hyperplasia/atypia and adenoma) induced by NNK in
mouse lung; these proteins can be used as potential biomarkers for
early detection of lung carcinogenesis. As no single marker has
proven to be sensitive and speciﬁc enough for lung cancer, it is
apparent to realize that a panel of proteins will be the most
informative. Therefore, our study provides a signiﬁcant step
toward utilizing a well-deﬁned animal model to identify poten-
tially biologically relevant lung cancer biomarkers for a variety of
purposes including early detection and to monitor efﬁcacy of
chemopreventive/therapeutic agents. Our ﬁndings provide a
pivotal step toward understanding the changes taking place at
the protein level in the target tissue cellular environment that
plays an important role in cancer development. Future studies in
the NNK-A/J mouse model will need to be aimed toward analyzing
these proteins in surrogate tissue such as BALF and plasma if these
proteins are proven useful for the early detection of lung
adenocarcinoma and in clinical chemoprevention trials.
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